Exhibit 99.1
For Immediate Release
LIPOCINE SUBMITS NEW DRUG APPLICATION
TO FDA FOR ITS ORAL TESTOSTERONE
REPLACEMENT PRODUCT CANDIDATE, LPCN 1021
SALT LAKE CITY (August 31, 2015)
– Lipocine Inc. (NASDAQ Capital Markets: LPCN), a specialty pharmaceutical company, today announced that is
has submitted a 505(b)(2) New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") for
LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions
associated with a deficiency or absence of endogenous testosterone ("hypogonadism").
"Filing of the NDA for LPCN 1021
is a significant achievement for Lipocine and a major milestone toward bringing this potential testosterone replacement therapy
option to patients. LPCN 1021 has the potential both to improve the ease of use compared to the available formulations, including
topical gels and injections, and to overcome inadvertent testosterone transference risk to children and partners," said Dr.
Mahesh Patel, Chairman, President and CEO of Lipocine Inc. "We look forward to working closely with the FDA during the review
process.”
The NDA filing is supported by results
from Lipocine’s Study of Oral Androgen Replacement ("SOAR") pivotal Phase 3 clinical study (http://clinicaltrials.gov/show/NCT02081300)
evaluating efficacy and safety of LPCN 1021 in hypogonadal men with low testosterone. The study met its primary efficacy endpoint
by successfully restoring testosterone levels to the normal range in 88% of the subjects. In addition, 85% of the subjects reached
their final dose with no more than one dose titration. LPCN 1021 treatment was well tolerated with no hepatic, cardiac, gastrointestinal
or drug related serious adverse events.
About LPCN 1021
LPCN 1021 is a twice-a-day, oral testosterone
replacement therapy product candidate with three simple oral dosing options that Lipocine expects will overcome the major shortcomings
of existing products. The current testosterone market is dominated by topical products that carry FDA "black box" warnings
related to inadvertent transfer of testosterone and by injectable products. The IMS Health database shows that an average of half
a million prescriptions a month have been dispensed so far in 2015 for TRT.
About Lipocine
Lipocine Inc. is a specialty pharmaceutical
company developing innovative pharmaceutical products for use in men's and women's health using its proprietary drug delivery technologies.
A New Drug Application was filed with the FDA for Lipocine's lead product candidate, LPCN 1021. LPCN 1021 demonstrated positive
- efficacy and safety results in Phase 3 testing and is targeted for testosterone replacement therapy. Additional pipeline candidates
include LPCN 1111, a next generation oral testosterone replacement therapy product with once daily dosing, that is currently in
Phase 2 testing, and LPCN 1107, which has the potential to become the first oral hydroxyprogesterone caproate product indicated
for the prevention of recurrent preterm birth with orphan drug designation, is currently in Phase 1 testing.
Forward-Looking Statements
This release contains "forward looking statements"
that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements
that are not historical facts relating to expectations regarding the FDA review process relating to our NDA for LPCN 1021 and the
outcome of such process, clinical trials, the potential uses and benefits of Lipocine's product candidates, product development
and commercialization efforts and the projected timing and outcome of regulatory filings. Investors are cautioned that all such
forward-looking statements involve risks and uncertainties, including, without limitation, the risks related to our products, expected
product benefits, clinical and regulatory expectations and plans, regulatory developments and requirements, risks related to the
FDA's review of our NDA for LPCN 1021, the receipt of regulatory approvals, the results of clinical trials, patient acceptance
of Lipocine's products, the manufacturing and commercialization of Lipocine's products, and other risks detailed in Lipocine's
filings with the U.S. Securities and Exchange Commission (the “SEC”), including, without limitation, its Form 10-K
and other reports on Forms 8-K and 10-Q, all of which can be obtained on the Company’s website at www.lipocine.com or on
the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained
in this release, except as required by law.
CONTACT:
Morgan Brown
Executive Vice President & Chief Financial Officer
Phone: (801) 994-7383
Email: mb@lipocine.com
John Woolford
Phone: (443) 213-0500
john.woolford@westwicke.com
# # #